Patient reported outcomes (pros) of multiple myeloma (MM) patients from the panorama-1 study who have received at least two prior regimens including bortezomib and an immunomodulatory agent

This article has no abstract
Epistemonikos ID: d34d9cc8a14a129e220dd43adce3121af8323e48
First added on: Feb 08, 2025